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A B S T R A C T
The use of the synthetic antioxidant ethoxyquin (6-ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline; EQ) in animal
feed results in the presence of EQ residues and metabolites, including the EQ dimer (1,8′-bi(6-ethoxy-2,2,4-
trimethyl-1,2-dihydroquinoline); EQDM) in animal food products. To investigate the toxicity and dose-response
of dietary exposure to EQDM, male BALB/c mice were exposed to one of six dietary doses of EQDM, ranging from
0.015 to 518mg/kg body weight/day for 90 days. Doses above 10mg/kg body weight/day aﬀected whole body
lipid metabolism resulting in increased liver weights and decreased adipose tissue mass. Metabolomic screening
of livers revealed alterations indicating incomplete fatty acid β-oxidation and hepatic oxidative stress.
Histopathological evaluation and biochemical analyses of the liver conﬁrmed the development of microvesicular
steatosis and activation of the glutathione system. Hepatic protein proﬁling and pathway analyses suggested that
EQDM-induced responses are mediated through activation of CAR/PXR nuclear receptors and induction of a
NRF2-mediated oxidative stress response. Based on the development of microvesicular steatosis as the critical
endpoint, a Reference Point for dietary EQDM exposure was established at 1.1 mg/kg body weight/day
(BMDL10) from benchmark dose modelling. Applying an uncertainty factor of 200, an Acceptable Daily Intake of
0.006mg EQDM/kg body weight was proposed.
1. Introduction
Ethoxyquin (6-ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline; EQ) is
a synthetic antioxidant, which has been widely used in animal feed for
pets, livestock and farmed ﬁsh as a technological additive to protect
against lipid peroxidation. EQ is not authorized as a food additive in the
European Union. The presence of EQ in feed for livestock and farmed
ﬁsh results in residues of EQ and its metabolites in edible tissue of
animal origin (Bohne et al., 2008; Lundebye et al., 2010; Hobson-
Frohock, 1982; Wang et al., 2015; He and Ackman, 2000). Thus, hu-
mans can be exposed to EQ residues and metabolites through their diet.
An Acceptable Daily Intake (ADI) of 0.005mg/kg body weight was
established for EQ and several metabolites by the Joint Food and
Agricultural Organization and World Health Organization Meeting on
Pesticide Residues (JMPR) based on clinical signs observed in dogs
exposed to 2.5mg EQ/kg body weight in feed (JMPR, 1998). However,
this ADI was not conﬁrmed by the European Food Safety Authority
(EFSA) in its review of the Maximum Residue Levels (MRLs) for EQ as a
pesticide (EFSA, 2013).
In addition to the parent compound, the ADI for EQ set by the JMPR
also included the intake of three metabolites found in plants, namely
methylethoxyquin, dihydroethoxyquin and dehydrodemethylethox-
yquin (Gupta and Boobis, 2005; EFSA, 2013). In salmon, EQ from ﬁsh
feed is rapidly metabolized (Skaare and Roald, 1977) to at least 14
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transformation products (Bohne et al., 2007a). Three ubiquitous me-
tabolites have been identiﬁed in salmon muscle: EQ quinone imine,1 de-
ethylated EQ2 and EQ dimer (EQDM)3 (Bohne et al., 2008), of which
EQDM, the main metabolite, usually accounts for> 90% of the sum of
EQ and EQDM (Lundebye et al., 2010; Bohne et al., 2008).
EQDM is regarded as an antioxidant in its own right (de Koning,
2002), and because EQDM is more lipophilic than EQ (Błaszczyk et al.,
2013), it can more readily accumulate in liver and adipose tissue. The
only study in the literature addressing the toxicity of EQDM in vivo,
found no adverse eﬀects on liver and kidney function in rats at a dose of
12.5 mg/kg body weight/day (Ørnsrud et al., 2011). However, the
EQDM-induced transcriptional responses of phase I and II bio-
transformation enzymes appeared to be comparable to those reported
for EQ (Ørnsrud et al., 2011), suggesting that EQDM and EQ may in-
duce similar biotransformation pathways. Furthermore, similarly to EQ,
EQDM has been reported to exhibit cytotoxic and genotoxic eﬀects on
human lymphocytes (Augustyniak et al., 2012). Still, the possible
health risk of EQDM from dietary sources for consumers has yet to be
characterized.
The aim of the present study was to investigate and characterize
possible adverse health eﬀects following 90 days dietary exposure to
EQDM in male BALB/c mice. Six graded doses of EQDM were ad-
ministered to the mice through the diet, and eﬀects on health status
were assessed in liver, kidney, spleen, blood and plasma.
A systems toxicology approach was employed in order to investigate
the mode of action and underlying molecular mechanisms of dietary
EQDM, using a multi-level -omics workﬂow as a screening tool to
characterize EQDM-induced changes in hepatic metabolomic and pro-
teomic proﬁles. The generated data were put into biological context
using systems biology bioinformatic tools, and the signiﬁcance of the
metabolic pathways identiﬁed as potential targets of dietary EQDM for
adverse outcomes was further consolidated using physiological and
biochemical analyses of relevant toxicological endpoints. Moreover,
guidance values for the upper level of intake of EQDM were derived
using the benchmark dose (BMD) and the No-Observed–Adverse-Eﬀect-
Level (NOAEL) approach.
Using this integrated approach, we aimed to gain mechanistic in-
sight and a quantitative understanding of the potential toxicity of
dietary EQDM, and to contribute relevant knowledge for future risk
assessments of EQDM in the food chain.
2. Materials and methods
2.1. Ethical statement
The animal facility and experiments were approved by the National
Animal Research Authority at the Norwegian Food Safety Authority
(approval identiﬁcation no. 8835). Animal handling and experimental
procedures were carried out in accordance with national and interna-
tional ethical standards.
2.2. Experimental diets
Eight diﬀerent feeds were produced; a control, six feeds spiked with
EQDM and, for reference, one feed spiked with EQ. The feed compo-
sition is given in Table 1. EQDM was administered as a crystalline
powder (> 95% purity; Synthetica AS, Oslo, Norway) mixed in a dry
powder feed based on the puriﬁed AIN-93-M diet for maintenance of
adult rodents. EQ (Capsoquin S-5162, 99% purity; courtesy of Industrial
Técnica Pecuaria, S.A., Spain) was dissolved in the dietary oil and then
blended into the dry diet. Ash, gross energy-, crude protein-, and total
fat content were measured as previously described by Tastesen et al.
(2014). The diets contained equal amounts of fat and protein, and were
isocaloric.
2.3. Animals and feeding experiment
Eighty male BALB/c mice, six weeks of age, were obtained from
Charles River (Germany). Following 10 days of acclimation on control
diet (AIN-93-M; EQDM 0), a 90 day subchronic dietary exposure study
was performed (in accordance with OECD guideline 408), using six
doses of EQDM (0.1, 1, 100, 1000, 3000 and 5000mg/kg feed), one
dose of EQ (1000mg/kg feed) and an unspiked control. The mice were
housed individually and kept at room temperature (20–22 °C), with a
relative humidity of 45–65% and a 12 h light/dark cycle (lights on
7a.m.). Throughout the experiment, the mice were monitored daily.
Water and feed, available ad libitum, were changed three times per week
and feed intake was recorded.
2.4. Body weight development and body composition
Body weight was recorded once a week. Whole body composition
was determined at the start of the study and after 12 weeks using a
nuclear magnetic resonance spectrometer (minispec LF50 Body
Composition Analyzer mq 7.5, Bruker Optik GmbH, Germany).
Animals exposed to a single dose of EQ comparable to the highest
dose of EQDM (EQDM 6) refused their feed and, after ten days, the mice
had lost 11% of their initial body mass. The animals appeared otherwise
healthy and showed an immediate reaction to the EQ-containing feed.
Possibly, sensory properties (taste and odour) of EQ (Błaszczyk et al.,
2013) caused the observed reduction in feed intake aﬀecting the pa-
latability at the given concentration. The dose of EQ was therefore re-
duced to 1000mg/kg feed (Table 1). The animals accepted the lower
dose and started gaining weight. Thereafter, body weight gain of ani-
mals in the EQ group was comparable to body weight gain in all of the
other groups. However, due to the initial lag in growth, the body weight
of animals in the EQ group remained markedly lower compared to
EQDM-exposed mice until the termination of the experiment. Since
diﬀerences between animals exposed to EQ and animals exposed to
EQDM for any measured parameter could not be diﬀerentiated from
eﬀects resulting from the deviations in feed intake and the subsequent
lower body weight, the animals exposed to EQ were excluded from the
study. All data collected for EQ-exposed mice can be found in Supple-
mentary ﬁle B.
2.5. Plasma and tissue sampling
Mice were sacriﬁced inducing pneumothorax under isoﬂurane an-
esthesia (Isoba vet, Schering-Plough, Denmark). Blood from cardiac
puncture was collected in EDTA-coated tubes, and a complete blood cell
count was performed on fresh whole blood using a VetScan HM5 he-
matology analyzer (Abaxis Europe GmbH, Germany). Plasma and red
blood cells were separated by centrifugation (15min at 2500 g and 4 °C
Microlite Microfuge, Thermo Electron Corporation) and stored at
−80 °C for further analyses. Organs were immediately dissected out,
weighed and either snap-frozen in liquid nitrogen and stored at−80 °C,
or ﬁxed in 4% paraformaldehyde. No gross pathologies were observed
in any of the animals.
2.6. Ethoxyquin (EQ) and ethoxyquin dimer (EQDM) measurements
EQ and EQDM were extracted from pooled samples of liver, spleen
and kidney (n= 10/pool) with hexane after saponiﬁcation in ethanol-
NaOH, while EQ and EQDM from feed samples were extracted directly
with 0.1% (w/v) solid acetic acid in acetonitrile. The concentrations of
EQ and EQDM were quantiﬁed by reversed-phase high-performance
liquid chromatography with ﬂuorescence detection, using an external
1 2,6-dihydro-2,2,4-trimethyl-6-quinolone.
2 6-hydroxy-2,2,4-trimethyl-1,2-dihydroquinoline.
3 1,8′-bi(6-ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline).
A. Bernhard et al. Food and Chemical Toxicology 118 (2018) 608–625
609
standard curve, as previously described by Bohne et al. (2007a), with
modiﬁcations described by Ørnsrud et al. (2011).
Of note, the measurement of EQ and EQDM revealed presence of ca.
3% EQ of the sum of EQ and EQDM in each of the EQDM-spiked ex-
perimental diets (Table 1), which were conﬁrmed as residues from the
synthesized EQDM powder. According to previous reports, EQ typically
accounts for a minor part of the sum EQ and EQDM found in farmed
Atlantic salmon ﬁllets exposed to EQ through their diet and reared
according to commercial farming practice (Bohne et al., 2008;
Lundebye et al., 2010). Although not optimal in terms of experimental
design, the presence of minor concentrations of EQ may be considered
as relevant for human exposure.
2.7. Liver metabolomic proﬁling
In order to identify possible eﬀects on liver metabolism, global
metabolite proﬁles were determined in individual liver samples of three
randomly chosen mice from each experimental exposure group. Semi-
quantitative metabolomic analysis was performed by Metabolon Inc.
(NC, USA), according to Metabolon's standard methods. Brieﬂy, after
addition of recovery standards, samples were extracted and prepared
for analysis using the automated MicroLab STARⓇ system (Hamilton
Company, NV, USA). The extracted samples were subsequently divided
into four fractions and analyzed using a combination of reverse-phase
ultra-performance liquid chromatography mass spectrometry (UPLC-
MS/MS) with positive and negative ion mode electrospray ionization
(ESI), and hydrophilic interaction (HILIC) UPLC-MS/MS with negative
ion mode ESI along with several internal standards. All methods uti-
lized a Waters ACQUITY UPLC and a Thermo Scientiﬁc Q-Exactive high
resolution/accurate mass spectrometer coupled to a heated ESI source
and an Orbitrap mass analyzer operated at 35 000 mass resolution. The
MS analysis alternated between MS and data-dependent MSn scans
using dynamic exclusion and the scan range covered 70–1000 m/z.
Instrument variability was 4% for liver tissue internal standards,
and total process variability for endogenous metabolites was 8% in the
samples. Known compounds were identiﬁed by comparison to meta-
bolomic library entries of puriﬁed standards.
2.8. Liver proteomic proﬁling
To further investigate possible eﬀects on molecular pathways, pro-
teomic proﬁles were determined in liver samples. To facilitate in-
tegration of the protein and metabolite proﬁles, individual samples
from the same three mice previously chosen for metabolomics analyses
were used for the proteomic proﬁling. Sample preparation, protein
identiﬁcation and quantiﬁcation were performed at the Proteomics Unit
at the University of Bergen, Norway (PROBE), according to standar-
dized protocols. In brief, 20–50mg liver samples were incubated at
95 °C for 7min in 10 μl lysis buﬀer/mg tissue (4% SDS, 0.1M Tris-HCl,
pH 7.6) and then lyzed by sonication, using a ultrasonication rod (Q55
Sonicator, Qsonica, CT, USA) at 30% amplitude for 30 s, or until tissue
was dissolved. The lysed tissue was centrifuged for 10min at 13000 rpm
and the supernatant was collected for determination of protein con-
centration using a Pierce™ BCA Protein assay kit (Thermo Scientiﬁc).
1M DiThiotreitol was added to the lysates, to obtain a ﬁnal con-
centration of 0.1M, and the mixture was incubated at 95 °C for 5min.
The samples were further processed using a Filter Aided Sample
Preparation (FASP) protocol with trypsin digestion as described by
Wiśniewski et al. (2009).
Between 0.5 and 1 μg protein (as tryptic peptides dissolved in 2%
acetonitrile and 0.1% formic acid) was injected into an Ultimate 3000
RSLC system (Thermo Scientiﬁc, CA, USA) connected online to a linear
Table 1
Composition of the experimental diets fed to male BALB/c mice for 90 days.
Component Dietary treatment
Control EQDM 1 EQDM 2 EQDM 3 EQDM 4 EQDM 5 EQDM 6 EQ†
Stated
Ethoxyquin dimer (mg/kg)a 0 0.1 1 100 1000 3000 5000 0
Ethoxyquin (mg/kg)b 0 0 0 0 0 0 0 (5000) 1000
Casein powder (g/kg) 140 140 140 140 140 140 140 140
Soy bean oil (g/kg) 40 40 40 40 40 40 40 40
Sucrose (g/kg) 100 100 100 100 100 100 100 100
Potatoe starch. dextrinized (g/kg) 125 125 125 125 125 125 125 125
Corn starch (g/kg) 496 496 496 496 496 496 496 496
L-Cystine (g/kg) 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8
Cellulose (g/kg) 50 50 50 50 50 50 50 50
t-Butylhydroquinone (g/kg) 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Mineral mix (g/kg)c 35 35 35 35 35 35 35 35
Vitamin mix (g/kg)d 10 10 10 10 10 10 10 10
Choline Bitartrate (g/kg) 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Analyzede
Ethoxyquin (mg/kg) < LOQ <LOQ 0.02 3 27 69 115 (3743) 1049
Ethoxyquin dimer (mg/kg) < LOQ 0.13 0.75 88 931 2501 4481 (< LOQ) 3
EQ & EQDM (mg/kg) < LOQ 0.13 0.77 91 958 2570 4596 (3743) 1052
%EQ 0 2.7 3.4 2.9 2.8 2.6 (100) 99.7
Crude protein (N*6.25) 131 128 131 131 130 134 132 130
Lipid (g/kg) 39 41 41 41 41 40 38 41
Ash 30 30 30 33 30 30 28 30
Gross energy (kcal/g) 4.1 4.1 4.2 4.1 4.1 4.1 4.1 4.1
†Intended and measured concentration in feed before (given in parentheses) and after intervention.
a Synthetica AS, Oslo, Norway (> 95% purity).
b Capsoquin S-5162, Industrial Técnica Pecuaria, S.A., Spain (99% purity).
c AIN 93G MIN MIX (M) (product number 829912; Special Diet Services, Witham Essex, England).
d AIN-93-VX NCR95 compliant vitamin mix (product number 829905; Special Diet Services, Witham Essex, England).
e Analyzed values represent the mean of technical duplicates.
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quadrupole ion trap-orbitrap (LTQ-Orbitrap Elite) mass spectrometer
(Thermo Scientiﬁc, Bremen, Germany) equipped with a nanospray Flex
ion source (Thermo Scientiﬁc). Samples were loaded and desalted on a
pre-column (Acclaim PepMap 100, 2 cm×75 μm ID nanoViper
column, packed with 3 μm C18 beads) at a ﬂow rate of 5 μl/min for
5min with 0.1% triﬂuoroacetic acid. Peptides were separated using a
biphasic acetonitrile gradient from two nanoﬂow UPLC pumps (ﬂow
rate of 270 nl/min) on a 50 cm analytical column (Acclaim PepMap
100, 50 cm×75 μm ID nanoViper column, packed with 3 μm C18
beads). Solvent A and B were 0.1% triﬂuoroacetic acid (vol/vol) in
water and 100% acetonitrile, respectively. The gradient composition
was 5%B during trapping (5min) followed by 5–7% B (over 1min),
7–21% B (134min), 21–34% B (45min), and 34–80% B (10min).
Elution of very hydrophobic peptides and conditioning of the column
were performed during 20min isocratic elution with 80% B and 20min
isocratic elution with 5% B respectively.
The eluting peptides from the LC-column were ionized in the elec-
trospray and analyzed by the LTQ-Orbitrap Elite. The mass spectro-
meter was operated in the data-dependent-acquisition (DDA)-mode to
automatically switch between full scan MS and MS/MS acquisition.
Instrument control was through Tune 2.7.0 and Xcalibur 2.2. Survey
full scan MS spectra (from m/z 300 to 2.000) were acquired in the
Orbitrap with resolution R=240 000 at m/z 400 (after accumulation
to a target value of 1e6 in the linear ion trap with maximum allowed
ion accumulation time of 300ms). The 12 most intense eluting peptides
above an ion threshold value of 3000 counts, and charge states 2 or
higher, were sequentially isolated to a target value of 1e4 and frag-
mented in the high-pressure linear ion trap by low-energy collision-
induced-dissociation (CID) with normalized collision energy of 35%
and wideband-activation enabled. The maximum allowed accumulation
time for CID was 150ms, the isolation with maintained at 2 Da, acti-
vation q= 0.25, and activation time of 10ms. The resulting fragment
ions were scanned out in the low-pressure ion trap at normal scan rate,
and recorded with the secondary electron multipliers. One MS/MS
spectrum of a precursor mass was allowed before dynamic exclusion for
40s. Lock-mass internal calibration was not enabled.
Prior to statistical analysis, the proteomics data were further pro-
cessed using MaxQuant as described by Tyanova et al. (2016). In short,
MaxQuant (Cox and Mann, 2008) running the built-in search engine
Andromeda (Cox et al., 2011) and protein sequences of the complete
mouse proteome downloaded from Uniprot (Magrane and UniProt
Consortium, 2011) were used for protein identiﬁcation and quantiﬁ-
cation. For protein identiﬁcation, carbamidomethylation of cysteines
and protein N-terminal acetylation as well as oxidation of methionines
were set as ﬁxed modiﬁcation and variable modiﬁcation, respectively.
Precursor mass tolerance was set to 4.5 ppm and 20 ppm were used for
fragment ion identiﬁcation. Up to two missed cleavages were allowed
for trypsin digestion. Within MaxQuant, the software option “Match
between runs” was enabled. The false discovery rates (FDR) for peptide
and protein identiﬁcation were set to 1%. Only unique peptides were
used for label-free quantiﬁcation (LFQ) according to the method de-
scribed by Cox et al. (2014). Relevant protein expression data including
LFQ intensities, statistical signiﬁcance, fold changes, and protein
identiﬁcation features including accession numbers, protein names,
isoelectric point, molecular weight, as well protein identiﬁcation me-
trics are provided in Supplementary ﬁle A, Tables S16 and S17.
2.9. Histopathological evaluation of liver, spleen and kidney tissue
Following dissection, liver, spleen and kidney tissue were ﬁxed in
neutral buﬀered formaldehyde (4%) and shipped to the Pathology
section at the Norwegian Veterinary Institute for histopathological
evaluation. The ﬁxed tissue samples were dehydrated, paraﬃn em-
bedded, sectioned (3 μm) and stained with hematoxylin and eosin (H&
E) for morphological evaluation. The histopathological ﬁndings were
categorized according to severity or characteristics and number of
animals in each category was recorded. Histopathological evaluation
was performed blinded by two pathologists. The results are presented as
quantal data (% presence).
2.10. Plasma biochemistry
Plasma concentrations of biochemical markers, including albumin,
total protein, glucose, total cholesterol, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phosphatase, bile
acids, bilirubin, creatinine, urea, triacylglycerides (TAG) and free fatty
acids (FFAs) were measured with an automated MaxMat PL II diag-
nostic analyser system (MAXMAT S.A., Montpellier, France) using kits
from DIALAB GmbH (Neudorf, Austria) and MaxMat (Montpellier,
France).
Concentrations of plasma sodium and chloride were determined
using an ABL 77 blood gas and electrolyte analyzer (Radiometer
Copenhagen, Denmark).
2.11. Redox status in liver
In order to assess changes in redox status and presence of oxidative
stress in the liver, the concentrations of reduced and oxidized glu-
tathione (GSH and GSSG, respectively), Vitamin E and thiobarbituric
acid reactive substances (TBARS) were quantiﬁed in liver tissue. For
quantiﬁcation of GSH and GSSG, frozen liver tissue samples were
weighed and homogenized in either 4x volume (v/w) of ice-cold 0.9%
saline buﬀer (9 g/L NaCl in ddH2O), or 2x volume (v/w) of ice-cold
thiol scavenger (N-ethylmaleimide pyridine derivative solution, Cat.
No. GT35c; Oxford Biomedical Research, MI, USA) diluted 3:7 in 0.9%
saline buﬀer, respectively, using a ball mill (25 rpm for 1–2min; Retsch
MM301 ball mill, Haan, Germany). The homogenates were centrifuged
(5min, 1500g, 4 °C), and GSH and GSSG were measured in the super-
natant using the Cuvette Assay kit for GSH/GSSG (Cat. No. GT35;
Oxford Biomedical Research, MI, USA) following the manufacturer's
instructions.
Vitamin E was extracted from homogenized pools of liver samples
(n= 10/pool) from all animals in each exposure group with hexane,
after saponiﬁcation with ethanol/KOH. Alpha-tocopherol concentra-
tions were quantiﬁed by high-pressure liquid chromatography with
ﬂuorescence detection, using an external standard curve as described
by Lie et al. (1994).
Finally, lipid peroxidation was assessed through measurement of
TBARS in individual liver samples of four randomly chosen mice from
each experimental exposure group. The concentrations of TBARS were
determined spectrophotometrically as described by Hamre et al.
(2001).
2.12. Liver lipid classes
Tissue lipids were extracted with chloroform:methanol, 2:1 (v/v)
from individual liver samples of four randomly chosen mice from each
exposure group, and lipid classes were quantiﬁed using High
Performance Thin Layer Chromatography (HPTLC) according to the
method previously described by Torstensen et al. (2011).
2.13. Statistical analyses and bioinformatic analyses of multi-level omics
data
All statistical data analyses were performed using R (version 3.4.0
(R Core Team, 2017)). Data were analyzed employing one-way ANOVA
followed by Tukey's test for multiple comparison of group means.
Normal distribution of the model residuals and homogeneity of var-
iance amongst treatment groups were tested with Shapiro-Wilk's test
and Levene's F-test, respectively. Data not meeting the assumptions of
ANOVA, were analyzed using Kruskal-Wallis’ test, and Wilcoxon's test
for multiple pairwise comparison of group ranks. For measurement of
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alpha tocopherol levels in pooled liver samples, a dose-response was
tested on the means of two technical replicates by a simple linear re-
gression model using the statistical software GraphPad Prism version
7.03 (GraphPad Software Inc.). Histological data were analysed by
Pearson's (level of conﬁdence 95%) followed by pairwise comparisons
of treated groups with the control group using two-tailed Fisher Exact
Test using GraphPad. Results are presented as mean ± standard de-
viation (SD).
The Qlucore Omics Explorer version 3.1 (Qlucore AB, Lund,
Sweden) was used for data processing and statistical comparison of
metabolomic and proteomic proﬁles. Original scale raw area counts of
all biochemicals and proteins were re-scaled mean centering the in-
dividual count values for each respective biochemical, before log2
transformation. The data were analyzed using one-way ANOVA fol-
lowed by planned contrasts, comparing the liver metabolite and protein
proﬁles of each exposure group to the livers of unexposed animals. For
all statistical analyses, a p-value<0.05 was used as signiﬁcance cut-
oﬀ. The data were further explored by principal component analysis
(PCA) and hierarchical cluster analysis (HCA).
For the intergrated biological pathway analysis, Kyoto Encyclopedia
of Genes and Genomes (KEGG) and UniProt accession numbers of sig-
niﬁcantly (p < 0.05, ANOVA) altered metabolites and proteins were
imported into the Ingenuity Pathway Analysis software suite (IPA;
Quiagen, CA, USA). Biological network analysis (IPA Core Analysis with
default settings) was performed on successfully mapped features fol-
lowed by targeted IPA upstream and comparison analyses as described
in Rasinger et al. (2014).
2.14. Benchmark dose (BMD) analysis
BMD analysis was performed on all measured endpoints according
to the EFSA benchmark dose technical guidance (EFSA, 2017). Results
were obtained using the EFSA BMD online application (under devel-
opment; https://shiny-efsa.openanalytics.eu/app/bmd). Fitting bench-
mark dose models was based on the R-package PROAST (available from
http://www.rivm.nl/en/Documents_and_publications/Scientiﬁc/
Models/PROAST), versions 64.16 (continuous data) and 61.3 (quantal
data). Model performance was evaluated based on the Akaike in-
formation criterion (AIC). A default value of 2 units diﬀerence between
AICs is considered as the critical value by the EFSA (2017). BMD models
were accepted when the AIC of a ﬁtted model was lower than the AIC of
the null model −2, and and the model with lowest AIC (AICmin) was
lower than the AIC of the full model +2 (AICmin < AICfull+2)
(EFSA, 2017). For endpoints representing measurements on a con-
tinuous scale, two models (model 3 and 5) were considered from the
exponential and hill model families, and the model with the lowest AIC
was selected as the model for calculating the BMD conﬁdence interval,
the lower bound is reported by BMDL and the upper bound by BMDU.
Averaging results from a default set of ﬁtted models, based on the
methodology in Wheeler and Bailer (2008), was available for BMD
analysis of quantal data and, as recommended (EFSA, 2017), applied to
ﬁndings from histopathological evaluation of tissues.
The default benchmark response (BMR) of 5% was used as the
starting point for model ﬁtting of continuous data (BMDL05). However,
as described in the EFSA technical guidance, the level of response was
adjusted where a wide conﬁdence interval (BMDU/BMDL) indicated
low precision of the estimates or based on biological considerations
(EFSA, 2017), and the BMDLs for BMRs of 10% or 20% changes above
the modelled background were considered (BMDL10 and BMDL20, re-
spectively).
For quantal data (histology) the default BMR was deﬁned as a
speciﬁed increase in incidence over background, and a BMR of 10%
(extra risk; BMDL10) was used as described by EFSA (2017). A 90%
conﬁdence interval around the BMD was estimated for each endpoint,
and a ﬁnal conﬁdence interval was derived using the lowest BMDL and
the highest BMDU. Taking biological relevance into account, poten-
tially critical endpoints were determined, and an overall critical BMDL
was derived from the obtained set of BMD conﬁdence intervals from
these endpoints as a Reference Point/Point-of-departure. The raw data
used for the analysis are available in Supplementary ﬁle A, Tables S1–6.
Table 2
Physical parameters of male BALB/c mice after 90 days dietary exposure to ethoxyquin dimer (EQDM). Results are presented as mean ± SD (n=10, unless
indicated otherwise; a: n= 7, b: n= 8, c: n=9).
Parameter Dietary treatment ANOVA (p)
Control EQDM 1 EQDM 2 EQDM 3 EQDM 4 EQDM 5 EQDM 6
Initial body weight (g) 21.0 ± 1.1 21.0 ± 1.1 21.0 ± 1.0 20.9 ± 1.0 21.0 ± 1.0 21.0 ± 1.0 21.0 ± 1.0 > 0.99
Feed intake (g) 299.4 ± 14.8 304.8 ± 10.3 296.6 ± 11.4 306.2 ± 9.0 291.5 ± 14.5 303.2 ± 12.4 296.2 ± 7.6 0.07
Total body weight gain (g) 8.7 ± 1.9 8.0 ± 1.9 8.9 ± 1.9 7.9 ± 1.5 8.8 ± 1.3 8.1 ± 1.8 7.0 ± 1.3 0.16
Final body weight (g) 29.7 ± 2.3 29.0 ± 1.8 29.9 ± 1.7 28.8 ± 1.7 29.8 ± 1.6 29.1 ± 1.7 28.0 ± 0.6 0.17
Estimated exposure EQDM (mg/kg
BW/day)
< LOQ 0.015 ± 0.001 0.081 ± 0.005 10 ± 1 99 ± 5 286 ± 22 518 ± 15
Estimated exposure EQ & EQDM
(mg/kg BW/day)
< LOQ 0.015 ± 0.001 0.084 ± 0.005 11 ± 1 102 ± 5 293 ± 22 531 ± 15
Body composition
Total body fat (g) 6.5 ± 2.8 5.8 ± 2.6 7.1 ± 1.7 6.2 ± 2.7 c 7.0 ± 2.0 5.3 ± 2.6 5.2 ± 0.9 0.35
Total body fat (% of BW) 22.3 ± 8.6 20.4 ± 8.3 24.7 ± 4.9 21.3 ± 8.3 c 23.9 ± 5.8 18.5 ± 8.1 19.3 ± 3.0 0.37
Total lean mass (g) 18.9 ± 0.9 18.8 ± 0.6 18.7 ± 0.5 18.9 ± 0.4 c 19.0 ± 0.5 19.4 ± 0.8 18.8 ± 0.4 0.15
Total lean mass (% of BW) 66.9 ± 6.0 68.2 ± 5.8 65.1 ± 3.4 67.5 ± 6.0 c 65.9 ± 3.9 69.6 ± 5.1 69.4 ± 1.7 0.29
Organ weights
Heart (g) 0.15 ± 0.01 0.14 ± 0.01 0.14 ± 0.02 0.14 ± 0.01 0.15 ± 0.02 0.15 ± 0.02 0.15 ± 0.01 0.73
Cardiosomatic Index (*100) 0.50 ± 0.03 0.49 ± 0.04 0.47 ± 0.04 0.50 ± 0.05 0.50 ± 0.04 0.50 ± 0.05 0.52 ± 0.05 0.46
Spleen (g) 0.077 ± 0.005 0.077 ± 0.005 0.082 ± 0.009 0.078 ± 0.008 0.079 ± 0.006 0.086 ± 0.012 c 0.081 ± 0.004 0.26
Spleenosomatic Index (*100) 0.26 ± 0.01 0.27 ± 0.01 0.27 ± 0.04 0.27 ± 0.03 0.26 ± 0.02 0.29 ± 0.03* c 0.29 ± 0.01* < 0.01
Liver (g) 1.14 ± 0.12 1.14 ± 0.10 1.17 ± 0.11 1.19 ± 0.12 1.39 ± 0.10* 1.63 ± 0.18* 1.60 ± 0.11* <0.001
Hepatosomatic Index (*100) 3.84 ± 0.22 3.93 ± 0.21 3.91 ± 0.30 4.11 ± 0.24 4.66 ± 0.25* 5.60 ± 0.37* 5.71 ± 0.38* <0.001
Kidneys (g) 0.40 ± 0.04 0.39 ± 0.01 0.39 ± 0.03 0.40 ± 0.02 0.39 ± 0.01 0.39 ± 0.03 c 0.40 ± 0.02 c 0.89
Renalsomatic Index (*100) 1.35 ± 0.16 1.36 ± 0.11 1.31 ± 0.07 1.38 ± 0.10 1.30 ± 0.08 1.35 ± 0.12 c 1.41 ± 0.09 c 0.29
Brain (g) 0.39 ± 0.04 a 0.41 ± 0.03 a 0.42 ± 0.02 a 0.42 ± 0.02 a 0.41 ± 0.03 b 0.41 ± 0.02 b 0.41 ± 0.01 b 0.56
White adipose tissue mass (g) 1.60 ± 0.30 1.54 ± 0.39 1.68 ± 0.29 1.44 ± 0.44 1.62 ± 0.31 1.29 ± 0.33* 1.16 ± 0.13* < 0.01
White adipose tissue mass (% of BW) 5.37 ± 0.67 5.25 ± 1.10 5.60 ± 0.78 4.93 ± 1.27 5.40 ± 0.78 4.42 ± 0.97* 4.13 ± 0.41* < 0.01
EQDM exposed groups were compared by one-way ANOVA with Tukey's post-hoc test, or where appropriate Kruskal-Wallis and Wilcox’ pairwise comparison.
*p < 0.05 compared to the Control.; Abbreviations: BW, Body weight.
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For the output of the model ﬁttings for all parameters, see Supple-
mentary ﬁle C.
3. Results
3.1. Physical parameters, hematology and tissue accumulation
To evaluate the potential toxicity of the EQ dimer (representing the
major metabolite of EQ found in salmon muscle), male BALB/c mice
(n=80) were exposed to EQDM at doses ranging from 0.015 ± 0.001
(EQDM 1) to 518 ± 15 (EQDM 6) mg/kg body weight/day for 90 days
(Table 2). Dietary exposure to EQDM did not aﬀect feed intake or body
weight gain (Table 2).
Crude body composition was assessed in an NMR analyzer. There
were no diﬀerences in total body fat mass or total lean body mass
among any of the groups. However, white adipose tissue mass (sum of
epididymal-, retroperitoneal- and inguinal white adipose tissue) was
signiﬁcantly decreased (p < 0.001) in mice fed the EQDM 5 and
EQDM 6 diets (Table 2). At the same time, the liver mass and hepato-
somatic indices increased gradually in mice exposed to EQDM at doses
above EQDM 3 (p < 0.001).
Compared to unexposed controls, a signiﬁcantly increased splee-
nosomatic index (p < 0.01) was observed in animals exposed to EQDM
5 and EQDM 6 (p < 0.01 and p < 0.001, respectively), as well as in
EQ exposed animals. No diﬀerences were observed in heart, kidney and
brain masses or relative organ weights. Tissue measurements of EQDM
and EQ in liver, spleen and kidney veriﬁed a dose-dependent accumu-
lation in all tissues (Supplementary ﬁle A, Table S7).
In order to assess general health status, a complete blood cell count
was performed (Supplementary ﬁle A, Table S8). Exposure to EQDM 5
and EQDM 6 resulted in a decreased volume percentage of red blood
cells (hematocrit) compared to control animals (p < 0.05; 8.9 and
13.37% decrease in EQDM 5 and EQDM 6, respectively). The lower
hematocrit levels were accompanied by gradually decreased mean
corpuscular volume, whereas no diﬀerences in hemoglobin concentra-
tions were observed (Supplementary ﬁle A, Table S8). No signiﬁcant
diﬀerences were observed among the groups in any other hematological
parameters, including total and diﬀerential white blood cell count
(Supplementary ﬁle A, Table S8). Further, the values for all measured
parameters were within the normal range for male BALB/c mice
(“Charles River Technical Resources: BALB/c Mouse” 2017). The de-
scribed changes were therefore not classiﬁed as pathological.
3.2. Liver metabolomic proﬁling and pathway analysis
To further investigate the possible eﬀects of dietary EQDM exposure
on the liver, an in-depth hepatic metabolic screening was performed.
Hepatic metabolite proﬁles of mice exposed to increasing dietary doses
of EQDM were examined using PCA and HCA, revealing clear changes
in metabolite proﬁles in livers from mice exposed to doses above EQDM
3 (Fig. 1A&B). Although the overall percentage of explained variance
on the ﬁrst two components was moderate (21% and 12%, respec-
tively), the PCA revealed a clear separation based on the dose of dietary
EQDM (Fig. 1A). Liver samples from mice exposed to low doses in-
cluding EQDM 1, 2 and 3 grouped together with samples from non-
exposed mice, whereas samples from mice exposed to doses higher than
EQDM 3 formed an overlapping population separating along both
components 1 and 2.
Of the 664 identiﬁed biochemicals, 184 compounds were sig-
niﬁcantly altered by dietary EQDM treatment (p < 0.05, ANOVA,
Supplementary ﬁle A; Table S10 for individual p-values). Classiﬁcation
of signiﬁcantly altered compounds using the KEGG superpathway an-
notations revealed a clear predominance of metabolites (62%) be-
longing to the “lipid” superpathway, followed by “amino acid” and
“cofactors and vitamins”, representing 21% and 6%, respectively, of all
signiﬁcantly aﬀected metabolites (Fig. 1C).
A dose-dependent increase in FFA levels was observed in livers from
animals exposed to diﬀerent doses of EQDM. EQDM 4 exposure led to
increased levels of all measured FFAs, including palmitate (16:0),
docosadienoate (22:2n-6) and docosatrienoate (22:3n-6; Fig. 2; Sup-
plementary ﬁle A, Table S11). Increased levels of FFAs may result from
increased fatty acid uptake, reduced fatty acid β-oxidation and/or hy-
drolysis of phospholipids or TAG. Signiﬁcantly higher levels of a
number of diacylglycerols and monoacylglycerols following a pattern
similar to the FFAs (Fig. 2), indicated a contribution of TAG hydrolysis
to the increased FFA pool.
The levels of some phospholipids, such as 14–16 GPCs, GPEs and 1-
stearoyl-2-oleoyl-GPS (18:0/18:1), were reduced in mice exposed to
doses higher than EQDM 3, whereas the levels of phospholipids in-
cluding 20–22C fatty acids increased (Fig. 2; Supplementary ﬁle A,
Table S11). However, a concomitant decrease of the phospholipid
Fig. 1. Principal component analysis (PCA) and hierarchical clustering analysis
(HCA) of signiﬁcantly altered metabolites in livers of BALB/c mice exposed to
increasing levels of ethoxyquin dimer (EQDM) through their feed. After 90 days
of exposure, livers (n= 3) were sampled and subjected to metabolomics ana-
lysis. Diﬀerential analysis (ANOVA), PCA (A) and HCA (B) were performed
using the Qlucore omics-explorer. For a complete overview of individual me-
tabolites, see Supplementary ﬁle A, Table S9 (C) The relative abundance of
signiﬁcantly altered (ANOVA, p < 0.05) liver metabolites in diﬀerent meta-
bolite categories.
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Fig. 2. Dose-dependent eﬀects on hepatic lipid metabolism in male BALB/c mice exposed to increasing dietary levels of ethoxyquin dimer (EQDM) for 90 days. The
heatmap shows the total of 114 individual lipid metabolites signiﬁcantly increased (red) or decreased (green) at each exposure level, grouped according to their
metabolic sub-pathway annotation. Scaled intensity means were used to calculate fold of increase or decrease of metabolites in each EQDM treatment group
compared to unexposed control animals. Signiﬁcance of diﬀerence was analyzed by t-test, with darker colours denoting signiﬁcantly (p < 0.05) aﬀected levels and
light colours denoting a signiﬁcance level of p < 0.1 compared to the control. Diﬀerences not meeting p < 0.1 are shown in black. For a complete list of calculated
fold-changes and exact p-values, see Supplemental ﬁle A, Table S11. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
Web version of this article.)
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breakdown products in mice exposed to doses higher than EQDM 3,
suggested that phospholipid breakdown did not contribute to increased
FFA levels.
Finally, high levels of FFAs may also result from decreased β-oxi-
dation. Mitochondrial fatty acid oxidation requires conversion of acyl-
CoA to acylcarnitine, and the levels of both long- and short chain
acylcarnitines were increased in a dose-dependent manner in the livers
of EQDM treated mice (Fig. 2). Concomitantly, the levels of the ketone
body 3-hydroxybutyrate were unaﬀected by EQDM treatment, whereas
the levels of the dicarboxylate fatty acid hexadecanedioate were sig-
niﬁcantly increased, suggesting incomplete mitochondrial β-oxidation
and channeling of fatty acids towards omega-oxidation in liver micro-
somes at doses above EQDM 3.
Further, increased levels of glycerol and glycerol-3-phosphate, as
well as increased levels of 3-phosphoglycerate and phosphoenolpyruvat
(PEP) were observed in mice exposed to doses higher than EQDM 4
(Fig. 3), indicating increased rates of glycolysis and/or inhibition of
further metabolic reaction of glycolytic intermediates downstream.
Taken together, the alterations of liver metabolite proﬁles in animals
exposed to EQDM indicated mobilisation of energy stores, and a dis-
ruption of fatty acid β-oxidation in liver mitochondria.
The glutathione system is responsible for maintaining redox
homoeostasis and preventing free radical damage in cells. A trend
towards increased levels of reduced glutathione levels (GSH) was de-
tected in mice exposed to EQDM 4 and EQDM 6 (Fig. 4). Notably, al-
though cysteine levels were not aﬀected by EQDM treatment, the levels
of cysteine sulﬁnic acid and hypotaurine, both dependent on cysteine,
were depleted in livers of mice exposed to EQDM doses above EQDM 3
(Fig. 4). Concomitantly, levels of the substrate for GSH synthetase,
gamma-glutamylcysteine, were signiﬁcantly increased (Fig. 4), sug-
gesting a redistribution of cellular cysteine stores towards increased
glutathione synthesis. Thus, the observed treatment-related changes on
the glutathione system indicated a compensatory induction of redox
capacity, due to depleted glutathione pools in the liver indicating a
disruption of liver redox-homeostasis and presence of oxidative stress.
The levels of n-6 fatty acid derived dihydroxy fatty acids 12,13-
DiHOME, and 14, 15-DiHETrE were signiﬁcantly elevated in mice ex-
posed to doses higher than EQDM 3 (Fig. 2). In addition, a trend to-
wards increased levels of 9,10 DiHOME was observed (p < 0.1) after
exposure to EQDM 5 and EQDM 6 (Fig. 2), indicating alterations in
inﬂammatory signaling and redox balance in response to high levels of
EQDM. In line with this, exposure to doses higher than EQDM 3 in-
creased the levels of some ceramides, including N-palmitoyl-sphingo-
sine (d18:1/16:0), N-stearoyl-sphingosine (d18:1/18:0)* and ceramide
(d18:1/17:0, d17:1/18:0)*, which can be produced by oxidative da-
mage to sphingomyelins and as such are lipid markers of oxidative
stress (Fig. 2). The levels of sphingomyelin decreased in livers of ani-
mals exposed to EQDM at levels higher than EQDM 4 (Fig. 2). Further,
the levels of plasmalogens, a class of phospholipids that are susceptible
to oxidative damage by free radicals, decreased concurrently. At the
same time, EQDM exposure at doses higher than EQDM 3 lead to a
depletion of Vitamin E (α-tocopherol and γ-CEHC glucuronide), which
act as lipid antioxidants (Fig. 5). Together, these results indicate that
exposure to high doses of EQDM leads to increased lipid peroxidation in
the liver.
To verify these ﬁndings, liver oxidative status was assessed through
direct measurement of concentrations of Vitamin E, TBARS, GSH and
GSGG. Measurement of hepatic alpha-tocopherol concentrations con-
ﬁrmed a linear dose-dependent depletion following EQDM exposure
(y = −0.004 mg/kg ww*Dose+44.33, F(1,5) = 7.559, p < 0.05, R2
of 0.602; Table 3). Direct measurement of hepatic GSH and GSSG
conﬁrmed a dose-dependent increase in GSH and GSSG levels
(p < 0.01, ANOVA; Table 3), which reached signiﬁcance in animals
exposed to doses above EQDM 4 (p < 0.05, ANOVA). The presence of
TBARS in the mice livers was generally very low, and levels were not
aﬀected by EQDM exposure.
3.3. Liver proteomic proﬁling and pathway analysis
In order to further investigate the mode of action of dietary EQDM,
proteomic proﬁling was performed in liver samples. PCA revealed clear
dose-dependent eﬀects of dietary EQDM exposure on liver proteome
proﬁles (Fig. 6A). Samples from animals exposed to doses lower than
EQDM 3 formed a cluster with minor separation of samples from ani-
mals exposed to both EQDM 1 and EQDM 2 from control animals along
the third component (5% of explained variance). Samples from animals
exposed to EQDM 3 moderately separated along the ﬁrst component
(59% of explained variance), forming an individual cluster close to the
samples of animals exposed to the lower doses, whereas samples from
animals exposed to EQDM 4 showed a distinct separation along the ﬁrst
component.
Samples from animals exposed to doses above EQDM 4 separated
further along the ﬁrst component and formed an overlapping popula-
tion. HCA echoed the distinct diﬀerences observed in the PCA between
animals exposed to low doses (including EQDM 3) and animals exposed
to higher doses (Fig. 6B). Also in agreement with the PCA, samples from
animals exposed to EQDM 3 clustered together with samples from an-
imals exposed to the lower doses, indicating that minor changes oc-
cured in the liver proteome following EQDM exposure at low dose
Fig. 3. Changes in levels of glycolytic metabolites in livers of mice exposed to
increasing doses of ethoxyquin dimer (EQDM) during 90 days. The plots show
scaled and mean centered intensities of the individual measurements in each
experimental group (n= 3/group), in addition to the mean and standard de-
viation represented by a line and whiskers. Metabolites signiﬁcantly aﬀected by
EQDM treatment (ANOVA) were further analyzed by t-test comparing each
exposure group to the control. Statistical signiﬁcance of pairwise comparisons is
denoted with *p < 0.05 compared to the control.
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levels. Samples from animals exposed to EQDM 4 formed an individual
cluster displaying substantial changes in proteome proﬁles similar to
animals exposed to EQDM 5 and EQDM 6.
Of the 2246 detected and quantiﬁed proteins, expression levels of
504 identiﬁed proteins were signiﬁcantly regulated by EQDM treatment
(p < 0.05; Supplementary ﬁle A, Table S17). To obtain insight into the
biological function of the alterations in the proteome proﬁle observed
after EQDM treatment at increasing doses, proteins detected at diﬀerent
abundances than in control animals (433; Supplementary ﬁle A, Table
S17) were grouped into larger functional categories, using the Ingenuity
Pathway Analysis (IPA) (Supplementary ﬁle A, Tables S19A–F). Similar
to the diﬀerences observed in individual protein expression proﬁles
induced by EQDM treatment at diﬀerent doses, distinct dose-dependent
responses were also detected at the pathway level, displaying a clear
onset of systemic responses after exposure to doses above EQDM 3.
Enrichment analysis of altered proteins against canonical pathway
annotations in IPA revealed a signiﬁcant overlap of treatment-related
changes in protein expression of several pathways (Fig. 7A). These in-
cluded pathways related to mitochondrial function (“mitochondrial
dysfunction”, “oxidative phosphorylation”), amino acid degradation,
energy metabolism (“TCA cycle II (eukaryotic)”, xenobiotic metabolism
(“xenobiotic metabolism signaling”, “PXR/RXR activation”), “estrogen
biosynthesis” and “fatty acid beta-oxidation I”. Closer examination of
altered proteins associated with the canonical pathway „mitochondrial
dysfunction“ in a network view suggested a disruption of the mi-
tochondrial respiratory chain (Fig. 7B). Causal network analysis of
protein expression data, where the directionality of the changes was
taken into account, highlighted a dose-dependent induction of the
“NRF2-mediated oxidative stress response” (z-score > 2) at doses
above EQDM 3, whereas “PPARa/RXRa activation” was inhibited (z-
score < 0) at doses above EQDM 4 (Fig. 7C).
To further elucidate the molecular mode of action of EQDM, an
Fig. 4. Treatment-related alterations in metabolites connected to cysteine and glutathione metabolism in livers of mice exposed to increasing levels of ethoxyquin
dimer (EQDM) through their diet for 90 days indicated changes in redox homeostasis and increased GSH biosynthesis. The plots show scaled and mean centered
intensities of the individual measurements in each experimental group (n=3/group), in addition to the mean and standard deviation represented by a line and
whiskers. Metabolites signiﬁcantly aﬀected by EQDM treatment (ANOVA) were further analyzed by a t-test comparing each exposure group to the control. Statistical
signiﬁcance of pairwise comparisons is denoted with *p < 0.05 compared to control.
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upstream regulator analysis was performed in IPA. This indicated that
changes observed in the liver following dietary EQ treatment were as-
sociated with dose-dependent activation of several transcription factors
and ligand-binding nuclear receptors (Fig. 8A), highlighting a likely
activation of NR1I2, NR1I3 and increasing PXR ligand-PXR-Retinoic
Fig. 5. Dose-dependent decrease of alpha-tocopherol and gamma-CEHC glu-
curonide, both important lipid anti-oxidants, in livers of mice exposed to in-
creasing levels of ethoxyquin dimer (EQDM) through their diet for 90 days. The
plots show scaled and mean centered intensities of the individual measurements
in each experimental group (n= 3/group), in addition to the mean and stan-
dard deviation represented by a line and whiskers. Metabolites signiﬁcantly
aﬀected by EQDM treatment (ANOVA) were further analyzed by a t-test com-
paring each exposure group to the control. Statistical signiﬁcance of pairwise
comparisons is denoted with *p < 0.05 compared to control.
Table 3
Oxidative stress markers in livers of male BALB/c mice exposed to increasing levels of ethoxyquin dimer (EQDM) for 90 days. Results are presented as mean ± SD, n
of individual measurements is given in parentheses. Liver α-tocopherol was measured in a sample pool of all animals for each exposure group (n= 1/group).
Dietary treatment P-values
Control (n) EQDM 1 (n) EQDM 2 (n) EQDM 3 (n) EQDM 4 (n) EQDM 5 (n) EQDM 6 (n)
Oxidative stress markers
GSH (uM) 6613 ± 786 (10) 6386 ± 826 (10) 6786 ± 763 (10) 6970 ± 413 (10) 7256 ± 897 (10) 7310 ± 878* (10) 7667 ± 737* (10) < .01
GSSG (uM) 11 ± 3 (10) 10 ± 2 (10) 12 ± 3 (10) 12 ± 2 (10) 14 ± 4* (10) 15 ± 3* (10) 15 ± 4* (10) < .01
GSH/GSSG 667 ± 195 (10) 635 ± 136 (10) 572 ± 114 (10) 579 ± 122 (10) 543 ± 165 (10) 495 ± 99 (10) 175 ± 338 (10) 0.19
TBARS (nmol/g ww) 0.9 ± 0.3 (4) 0.9 ± 0.2 (3) 1.2 ± 0.2 (4) 1.0 ± 0.4 (4) 0.9 ± 0.4 (4) 1.0 ± 0.3 (4) 1.3 ± 0.5 (4) 0.67
Vitamin E (mg/kg ww)
α-tocopherol 51.2 47.4 49.3 34.1 35.4 30.1 28.3 < .05†
EQDM exposed groups were compared by one-way ANOVA with Tukey's post-hoc test, or where appropriate Kruskal-Wallis and Wilcox’ pairwise comparison.
*p < 0.05 compared to the Control.
†The relationship between the dose of EQDM administered as predictor for hepatic α-tocopherol concentrations was tested in a simple linear regression model
including all data points (n = 7): Y = −0.003796*x+44.33, R2= 0.6019, p < 0.05.; Abbreviations: GSH; Glutathione (reduced), GSSG; Glutathione (oxidized),
TBARS; Thiobarbituric acid reactive substances.
Fig. 6. Principal component analysis (PCA) and hierarchical clustering analysis
(HCA) of signiﬁcantly regulated (p < 0.05, ANOVA) proteins in livers of
BALB/c mice. Mice were fed diets spiked with ethoxyquin dimer (EQDM) at
increasing doses. After 90 days of exposure, livers (n=3) were sampled and
subjected to proteomics analysis. Diﬀerential analysis (ANOVA), PCA (A) and
HCA (B) were performed using the Qlucore omics-explorer. See Supplementary
ﬁle A, Table S16 for a complete overview of individual proteins.
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Fig. 7. Ingenuity pathway analysis on proteins altered by subchronic dietary exposure to increasing doses of ethoxyquin dimer (EQDM) in livers of male BALB/c
mice. (A) According to the total number of aﬀected proteins, the analysis revealed “Mitochondrial dysfunction”, “oxidative phosphorylation”, “fatty acid beta-
oxidation I” among the top enriched canonical pathways. The top 25 pathways are presented. (B) Schematic overview over signiﬁcantly elevated ( ) or lowered (
> EQDM 3; > EQDM 4) levels of proteins related to the canonical pathway “mitochondrial function”, suggesting disruption of the mitochondrial respiratory chain
in livers of mice exposed to higher doses of EQDM. (C) Furthermore, including the direction of changes highlighted a signiﬁcant overlap for induction of the “NRF2-
mediated oxidative stress response”. For a full list of associated pathways, respective p-values of overlap and activation z-scores, see Supplementary ﬁle A, Table
S19B.
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acid-RXR activity, as well as inhibition of PPARA at exposure levels
above EQDM 3 (Fig. 8B). A dose-dependent eﬀect was predicted for the
transcription factor NFE2L2, with a signiﬁcant overlap for decreased
activity at the lowest exposure (EQDM 1) and a gradually increased
activation after exposure to doses above EQDM 2 (Fig. 8B). Further-
more, the comparison of the EQDM-induced changes on protein levels
with the literature compiled in the Ingenuity® Knowledge Base revealed
a signiﬁcant overlap with responses previously described for diﬀerent
drugs and chemicals, including phenobarbital and EQ (Fig. 8C).
3.4. Liver histopathology, lipid accumulation and oxidative stress status
Histological evaluation of liver sections revealed clear treatment
related changes (Table 4) reﬂecting both observed alterations in the
hepatic metabolite proﬁle (Fig. 2) and changes in hepatic lipid mea-
surements (Fig. 9A–B; Supplementary ﬁle A, Table S13), whereas no
treatment-related eﬀects were observed in a histopathological
screening of spleen and kidney tissue (data not shown). In liver sec-
tions, microvesicular lipid accumulation, most often both centrilobular
and midzonal, was observed in 50–60% of the animals exposed to
EQDM at levels higher than EQDM 3 (Fig. 9C), whereas hepatic stea-
tosis was observed in 0–10% of the animals belonging to the control
group, exposed to the lowest dose of EQDM (EQDM 1) or EQ (Table 4).
The lipid accumulation in each sample was not widespread, but rather
observed as scattered areas. Single cell necrosis was observed in all
groups (Fig. 9D). However, a signiﬁcantly higher proportion of animals
Fig. 8. Upstream regulator analysis (URA) of proteome changes induced by subchronic dietary exposure to increasing doses of ethoxyquin dimer (EQDM) in livers of
male BALB/c mice. The transcriptional regulators from the regulator category “Genes, RNAs and proteins” were predicted from signiﬁcantly altered levels of known
targets from the IPA database (A). Taking direction of change into account, the analysis highlighted several likely upstream regulators from the category “genes,
proteins and RNA”, including the transcription factor NFE2L2 and the nuclear receptors NR1I2, NR1I3 and PPARA showing a signiﬁcant overlap with responses
described in the literature (B) The top 25 transcriptional regulators are presented. Results from the regulator category “drugs/chemicals” showed a signiﬁcant overlap
of regulated proteins with both a response induced by phenobarbital, as well as ethoxyquin (C). For an unﬁltered output of the upstream regulator analyses, see
Supplementary ﬁle A, Table S19E.
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exposed to a higher dose than EQDM 3 had this lesion (Table 4).
Hepatic necrosis occurred as focal or multifocal lesions (Fig. 9D),
and the degree of necrosis was assessed as follows: 0= no necrosis
observed, 1= one necrotic focus (mild necrosis), 2= two or three ne-
crotic foci (moderate necrosis), and 3=more than three necrotic foci
(severe necrosis). Mild or moderate hepatic necrosis was observed in
one to three animals in all groups, whereas severe necrosis was present
in two to six animals exposed to doses of EQDM 4 and above (Table 4).
Bile pigment (hepatocellular and canalicular) was not observed after
EQDM exposure, except in one animal exposed to the highest dose
(EQDM 6; 518 ± 15mg EQDM/kg body weight/day).
As markers of impaired liver function and liver damage, ALT and
AST levels were measured in plasma (Fig. 9E–F). Plasma ALT levels
were signiﬁcantly increased in animals exposed to EQDM at doses
above EQDM 3 (p < 0.05), resulting in signiﬁcantly lower ratios of
AST/ALT (p < 0.001, Fig. 9G) in these groups. No changes were ob-
served in other plasma markers of organ function (Supplementary ﬁle
A, Table S14).
3.5. Benchmark dose assessment
The BMDL assessment was performed on average daily dose of
EQDM (mg/kg body weight/day) versus quantitatively measured bio-
logical parameters (Table 5).
Clear treatment-related eﬀects were observed for liver mass and
hepatosomatic index, of which hepatosomatic index with a BMDL05
4.4 mg EQDM/kg body weight/day was the lower one. No trend was
observed for spleen mass, but for the spleenosomatic index a BMDL05 of
110mg/kg body weight/day was established, which approximately
corresponded to the NOEL for this parameter (99.4 mg EQDM/kg body
weight/day). No BMD model could be ﬁtted for kidney masses
(Supplementary ﬁle C, Table S2).
The histopathological evaluation revealed morphological changes,
including increased occurrence of microvesicular steatosis and in-
creased presence of both single cell necrosis and necrotic foci in livers
of mice exposed to doses higher than 10mg EQDM/kg body weight/day
(NOAEL), which indicated adverse physiological eﬀects. At a dose level
of 0.01mg EQDM/kg body weight/day, increased occurrence of single
cell necrosis had the lowest BMDL10 of the histopathological para-
meters. Due to a very large BMDU/BMDL (< 10 000; Supplementary
ﬁle C, Table S3), and thus very high uncertainty regarding the assess-
ment, this ﬁnding was not considered for derivation of a critical BMDL.
Occurrence of more than two necrotic foci („severe necrosis“) had the
lowest BMDU/BMDL (18.3) ratio, and the BMDL10 of 10.3mg EQDM/
kg body weight/day was thus the most reliable estimate. However,
despite a higher BMDU/BMDL ratio, occurrence of microvesicular
steatosis had the lowest BMDL10 of 1.1mg/kg body weight/day.
Accumulation of lipid in the liver was associated with mobilization
of fatty acids from the adipose tissue stores. Thus, BMD conﬁdence
intervals were assessed for total liver lipid levels, the relative increase
in liver TAG (Supplementary ﬁle C, Table S5) and decrease of white
adipose tissue mass relative to body weight as adaptive responses and
thus possible biomarkers of an adverse eﬀect. Given that physiological
parameters of energy homeostasis, including mobilization of fat from
the adipose tissue stores to the liver for energy yield, show natural
individual and temporal ﬂuctuations, a 10% and 20% change from the
modelled background response was considered as eﬀect size for adipose
tissue and liver lipid measurements (total amount of liver lipid and %
liver TAG), respectively. The BMDL10 for white adipose tissue mass
relative to body weight was 11.7 mg EQDM/kg body weight/day. The
lowest BMDL20 was established at 4.5mg EQDM/kg body weight/day
for total liver lipid.
For plasma biomarkers of adverse eﬀects, a model could only be
ﬁtted for the liver enzyme ALT and the ratio of AST/ALT
(Supplementary ﬁle C, Table S4). Applying a default BMR of 5%, the
plasma marker of adverse eﬀect on liver, ALT had a rather high BMDU/
BMDL ratio (9412.5), indicating an unreliable BMD assessment and was
thus adjusted to 20%, providing a BMDL20 of 1.9mg EQDM/kg body
weight/day. For the ratio of AST/ALT, a BMDL05 was set at 5.7mg
EQDM/kg body weight/day.
Furthermore, BMDs were assessed for changes in liver GSH, vitamin
E and TBARS levels. These parameters were not considered adverse
eﬀect markers, but rather markers of exposure and therefore not taken
into account for evaluation of the critical BMDL. Given that physiolo-
gical parameters of energy and redox homeostasis, show higher natural
individual and temporal ﬂuctuations, a 10% change from modelled
background levels was applied. The BMD for increased GSH levels was
the most reliable estimate with a BMDU/BMDL ratio ∼23, and a
BMDL10 of 23.5 mg EQDM/kg body weight/day. For liver GSSG and
liver vitamin E levels, applying a BMR at 10% resulted in a low con-
ﬁdence prediction of the BMD (Supplementary ﬁle C, Table S7). Ap-
plying a BMR of 20%, the conﬁdence of the prediction for liver GSSG
levels had a BMDU/BMDL of ~22 and a BMDL20 of 10.0mg EQDM/kg
body weight/day. The lowest BMDL20 for vitamin E levels was esti-
mated to 0.2mg EQDM/kg body weight/day. No model could be ﬁt for
liver TBARS (ALL AIC > AICnull).
Table 4
Histological evaluation of liver tissue after 90 days of dietary exposure to ethoxyquin dimer (EQDM).
Observation Dietary treatment p-value
Control EQDM 1 EQDM 2 EQDM 3 EQDM 4 EQDM 5 EQDM 6
Steatosis 1/10 0/10 1/10 1/10 6/10 6/10 5/10 <0.01
Steatosis microvesicular 0/10 0/10 1/10 1/10 2/10 3/10 5/10* < 0.05
Steatosis macrovesicular 0/10 0/10 0/10 0/10 0/10 0/10 0/10 –
Steatosis mixed 1/10 0/10 0/10 0/10 4/10 3/10 0/10 <0.05
Single cell necrosis 2/10 2/10 3/10 1/10 5/10 9/10* 7/10 <0.01
Necrosis 2/10 3/10 2/10 2/10 5/10 8/10* 7/10 <0.05
Mild 1/10 3/10 1/10 1/10 2/10 1/10 1/10 0.80
Moderate 1/10 0/10 1/10 1/10 3/10 1/10 3/10 0.39
Severe 0/10 0/10 0/10 0/10 2/10 6/10* 3/10 <0.001
Accumulation of bile pigment 0/10 0/10 0/10 0/10 0/10 0/10 1/10 0.41
Frequencies of observations in EQDM exposed groups were compared using a Chi square test. A signiﬁcant ﬁnding was further examined comparing each group to the
control group using a two-tailed Fisher's Exact test. *p < 0.05 compared to the Control.
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Fig. 9. Total lipids (A) and triacylglycerides (TAG; B) in livers of male BALB/c mice after 90 days of dietary exposure to increasing doses of ethoxyquin dimer
(EQDM). (C) Liver tissue of mice fed control diet (EQDM 0- left panel), and mice exposed to doses above 10mg/kg body weight/day displaying increased occurrence
of centrilobular (mid panel) and midzonal (right panel) microvesicular steatosis (Table 4). H&E staining [scale bar: 100 μm]. (D) Liver tissue of mice exposed to doses
above 10 mg/kg body weight/day had an increased frequency of single cell necroses (left panel) and presence of necrotic foci (right panel). H&E staining [scale bar:
100 μm]. Measurement of plasma alanine transferase (ALT; E), aspartate transferase (AST; F) and their ratio (G), indicated compromised liver function in mice
exposed to higher doses of EQDM. Bar charts represent means ± SD of n = 4 (lipid measurements) and n = 8–10 (plasma markers of liver function). Statistical
signiﬁcant diﬀerences between EQDM exposed groups and control are indicated with *p < 0.05 (1-way ANOVA, Tukey's post hoc test).
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Finally, for hematological parameters, showing high biological
variability, a BMR of 10% was assessed. Although signiﬁcant changes
were observed for some hematological parameters comparing mice
from the individual dose groups to the control mice, none of the mea-
sured parameters fulﬁlled the AIC criteria (Supplementary ﬁle C, Table
S6), and the measurements were thus excluded from BMDL assessment.
An overview over the output, including the models, of the chosen
parameters is given in Supplementary ﬁle C, Table S1. In conclusion,
development of microvesicular steatosis was chosen as critical endpoint
with the lowest BMDL10 of 1.1mg EQDM/kg body weight/day. Ap-
plying an uncertainty factor of 200 to the BMDL10 we propose an ADI of
0.006mg/kg body weight for dietary exposure to EQDM.
4. Discussion
EQDM is one of the main metabolites present in ﬁsh exposed to EQ
through their feed, but health risks associated with dietary exposure to
EQDM in consumers are largely uncharacterized. The present study in-
vestigated eﬀects of subchronic dietary exposure to six doses of EQDM
ranging from 0.015 to 518mg/kg body weight/day in male BALB/c
mice. Integrative analysis of classical physiological markers of toxicity
and hepatic metabolite and proteome proﬁles revealed that dietary ex-
posure to EQDM led to metabolic changes and disruption of whole body
lipid metabolism at doses above 10mg/kg body weight/day.
In line with previous results on dietary EQDM exposure in rats
(Ørnsrud et al., 2011), in the present study, 90 days exposure to EQDM
did not aﬀect body weight in mice at doses up to 518mg/kg body
weight/day. However, a signiﬁcant dose-dependent increase in relative
liver mass was noted at doses of 99mg EQDM/kg body weight/day and
above (EQDM 4, EQDM 5, EQDM 6). Although overall body fat was not
aﬀected by EQDM treatment, a dose-dependent decrease in white adi-
pose tissue mass was observed, which indicated a mobilization of lipids
from adipose tissue stores and resulted in an accumulation of lipids in
the liver.
The dose-dependent accumulation of liver TAG manifested as in-
creased occurrence of microvesicular steatosis in animals given in-
creasing doses of EQDM. Because of its central role in metabolism, the
liver is an important target of toxicity for xenobiotics, and oxidative
stress (Jaeschke et al., 2002; Gu and Manautou, 2012). Hepatic stea-
tosis is a common consequence of toxic insult to the liver (Patel and
Sanyal, 2013; Begriche et al., 2011). Hepatic microvesicular steatosis is
a potentially severe liver lesion associated with drug-induced liver in-
jury, which is caused by impairment of fatty acid metabolism (Begriche
et al., 2011; Fromenty and Pessayre, 1995; Pessayre et al., 2010). In the
present study, substantial changes in the hepatic metabolite proﬁles
were observed following EQDM-exposure to doses of 99 mg/kg body
weight/day and above (EQDM 4, EQDM 5, EQDM 6), including ele-
vated levels of FFAs, reﬂecting increased lipid mobilisation through
TAG hydrolysis and hepatic uptake of fatty acids in the liver. Of note, a
dose-dependent accumulation of lipid intermediates, such as acylcar-
nitines in absence of increased levels of ketone bodies (Fig. 2), reﬂected
a lipid proﬁle typically associated with impaired mitochondrial fatty
acid β-oxidation (Pessayre et al., 2012). Inhibited fatty acid β-oxidation
may lead to increased levels of un-oxidized fatty acids in the liver. Non-
Table 5
Benchmark doses (BMD) and lower and upper 90% conﬁdence interval (BMDL and BMDU, respectively) for measured responses in male BALB/c mice exposed to
seven doses of EQDM ranging from 0.015 to 518mg/kg BW/day through their diet for 90 days. Taking biological variation into consideration, benchmark responses
(BMR) were set at the default of 5%, or adjusted to 10 or 20%. For derivation of the critical BMDL, the width of the conﬁdence interval was taken into account as an
indicator of estimate precision. The No-observed-(adverse)-eﬀect-levels (NOAEL/NOEL) were determined from statistical comparisons of responses in each pre-
determined dose group with the control group. From all endpoints assessed, the endpoints considered most biologically relevant (in bold) were included into
assessment of the critical BMDL.
Endpoint BMR (%) BMD BMDL lowest BMDU highest BMDU/BMDL NOAEL/NOEL
Necropsy
Liver weight 5 32.0 6.9 74.30 10.8 10
Liversomatic Index 5 24.7 4.4 70.9 16.2 10
Spleen weight 5 none none none
Spleenosomatic Index 5 200.0 110.0 334.0 3.0 99
Kidney weight 5 none none none
Renalsomatic Index 5 none none none
Histopathology
Microvesicular steatosis 10 8.8 1.1 240.8 227.0 286
Single cell necroses 10 23.5 0.01 136.6 10155.9 99
>2 Necrotic foci observed 10 42.6 10.3 188.0 18.3 99
Liver lipid
Total liver lipid 20 12.1 4.5 125.0 28.0 10
% Liver triacylglycerides 20 143.0 49.8 599.0 12.0 10
White adipose tissue mass 10 209.2 13.3 391.5 29.4 99
White adipose tissue mass/
body weight
10 206.3 11.7 386.7 33.2 99
Plasma biochemical markers
Alanine transferase (ALT) 20 48.2 1.9 108.0 58.1 10
Aspartate transferase (AST) 20 none none none
AST/ALT 5 33.1 5.7 49.7 8.7 10
Homeostatic responses redox homeostasis liver/Oxidative stress responses
Reduced glutathione (GSH) 10 83.8 23.5 551.0 23.4 99
Oxidized glutathione (GSSG) 20 32.4 10.0 217.0 21.7 10
Liver alpha tocopherol 20 4.9 0.2 17.1 87.7 NA
TBARS liver 10 none none none
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oxidized, non-esteriﬁed fatty acids are incorporated into TAG and ac-
cumulate in the form of small lipid droplets in the cytosol of hepato-
cytes, a hallmark of microvesicular steatosis (Begriche et al., 2006).
Hence, EQDM-induced impairment of fatty acid β-oxidation, as sug-
gested by proteomics and metabolomics analyses (Figs. 2 and 7) may
have contributed to accumulation of liver TAG and the on-set of liver
steatosis.
Increased frequency and severity of necrosis in livers of mice ex-
posed to 99mg/kg body weight/day and above, and concomitantly
elevated ALT levels in plasma indicated progression of steatosis to
steatohepatitis and thus an onset of liver damage. The mechanisms
involved in the progression of steatosis to steatohepatitis in drug-in-
duced liver damage are not well understood. However, it appears that
mitochondrial dysfunction and cellular oxidative stress from over-
production of reactive oxygen species (ROS) play key roles in the pa-
thogenesis of steatohepatitis (Begriche et al., 2011). The proteomics
analyses revealed an EQDM-induced enrichment of features associated
with mitochondrial dysfunction, mitochondrial oxidative phosphor-
ylation and NRF2-mediated oxidative stress response. A number of
steatohepatitis-inducing drugs are able to impair the mitochondrial
oxidative phosphorylation process and inhibit the mitochondrial re-
spiratory chain (Pessayre et al., 2012; Schumacher and Guo, 2015).
Inhibition of fatty acid β-oxidation is reported to impair oxidative
phosphorylation in the respiratory chain and ATP synthesis, and
thereby increase production of ROS and oxidative stress (Begriche et al.,
2011; Pessayre et al., 2012; Fromenty and Pessayre, 1995; Schumacher
and Guo, 2015). Furthermore, high levels of FFAs and elevated levels of
other lipid metabolites, including hydroxylated and dicarboxylic fatty
acids as observed in livers of mice treated with EQDM, promote lipo-
toxic conditions, which can induce mitochondrial dysfunction
(Fromenty and Pessayre, 1995, 1997; Begriche et al., 2011). Reduced
energy availability and direct oxidative damage from ROS may, in more
severe cases, induce hepatocyte necrosis (Begriche et al. 2006, 2011;
Pessayre et al., 2012). EQ has been reported to interfere with energy-
dependent mechanisms through inhibition of ATPase activity and dis-
rupt electron transport in the mitochondrial respiratory chain in both
liver and kidney of rats (Reyes et al., 1995; Hernández et al., 1993).
Based on the pathway analysis performed in the present study (Fig. 7B),
it appears, that also EQDM may disrupt the mitochondrial respiratory
chain.
Depletion of vitamin E, particularly associated with the detoxiﬁca-
tion of reactive lipid species, in livers of EQDM-treated mice (Fig. 5 and
Table 3), as well as elevated levels of lipid markers of oxidative stress
(ceramides; Fig. 2) indicated increased rates of lipid peroxidation. In-
duction of oxidative stress is a hallmark of toxicity, and the generation
of ROS is a natural consequence of xenobiotic biotransformation.
EQDM is reported to be a biphasic inducer of xenobiotic metabolism
(Ørnsrud et al., 2011), and may be biotransformed by liver microsomal
enzymes (CYPs) through a series of redox reactions, which generates
ROS (Guengerich, 2006; Klotz and Steinbrenner, 2017). In agreement
with a previous study on the eﬀects of EQ in mouse liver (Kim, 1991),
EQDM exposure was found to increase levels of reduced liver glu-
tathione (GSH; Fig. 4 and Table 3). A dose-dependent increase in oxi-
dized glutathione levels (GSSG) in livers of mice exposed to EQDM at
doses above EQDM 3, indicated perturbation of liver redox home-
ostasis. The observed concomitantly altered levels of cysteine-depen-
dent metabolites and increased levels of γ-glutamylcysteine synthetase,
the rate-limiting enzyme in glutathione biosynthesis (Fig. 4), suggested
a compensatory induction of glutathione synthesis.
EQ-induced glutathione (GSH) synthesis and regeneration has been
associated with the ability of EQ to activate the nuclear factor erythroid
2-related factor 2 (NRF2; also known as NFE2L2) signalling pathway
(Hayes et al., 2000). Xenobiotics activate NRF2 through suppression of
its negative regulator, KEAP1 (Kelch-like ECH-associated protein 1).
KEAP1 may be oxidized by increased levels of cytosolic ROS or elec-
trophiles originating from lipid peroxidation, which causes release of
the NRF2 from the NRF2-KEAP1 complex and translocation to the nu-
cleus. Subsequently, NRF2 activates transcription of target genes, in-
cluding genes that encode phase II enzymes such as GSTs, UGTs, NADP
(H):quinone oxidoreductase and epoxide hydrolase, as well as genes
encoding proteins involved in antioxidant responses, including γ-glu-
tamylcysteine synthetase, as observed in the present study (Kensler and
Wakabayashi, 2010; Hayes et al., 2000; Shen and Kong, 2009). Using
IPA as a bioinformatic tool, induction of the NRF2-mediated oxidative
stress response was predicted to represent an important EQDM target
pathway (Fig. 7C), indicating that EQDMmay act in a similar manner to
EQ.
Upstream regulator analysis based on hepatic proteomic proﬁles
substantiated a signiﬁcant overlap, predicting an activation of NFE2L2
by EQDM. This analysis further revealed that the changes observed in
the liver proteome were likely associated with activation of the orphan
nuclear receptors NR1I2 (also known as pregnane X receptor; PXR) and
NR1I3 (also known as constitutive androstane receptor; CAR), as well as
inhibition of peroxisome-proliferator activated receptor alpha (PPAR-
α). The nuclear receptors PXR and CAR were originally characterized as
xenosensors targeting enzymes of phase I and phase II metabolism of
xenobiotics, but accumulating evidence demonstrates a distinct role of
these receptors in maintaining energy homeostasis in the body (Wada
et al., 2009; Gao and Xie, 2010). Activation of both PXR and CAR is
associated with suppressed gene expression of PPAR-α (Wada et al.,
2009), a master regulator of hepatic FA β-oxidation (Rao and Reddy,
2001), and PXR-mediated inhibition of PPAR-α has been linked to the
development of microvesicular steatosis in transgenic mice (Zhou et al.,
2006). Interestingly, dietary exposure to 0.5% w/w EQ was found to
counteract the hepatocarcinogenic eﬀect of ciproﬁbrate in rats (Rao
et al., 1984). This could not be explained by an interference with per-
oxisome proliferation or peroxisome-associated enzymes (Lalwani
et al., 1983). Yet, EQ-induced CYP enzyme induction in rat liver mi-
crosomes has previously been described as similar to the response
produced by phenobarbital, a known CAR activator (Kahl and Netter,
1977). In ﬁsh, dietary exposure to EQ was found to induce expression of
CYP3A mRNA (Bohne et al., 2007a). As expression of CYP3A mRNA in
mammals is directly controlled by PXR (Staudinger et al., 2001; Xie
et al., 2000), the authors speculated whether EQ or its metabolites may
at least partly act through PXR mediated pathways (Bohne et al.,
2007b). In agreement with our ﬁndings, no eﬀect on regulation of
Cyp3a expression or CYP3A activity was observed in rat livers following
subchronic dietary exposure to a dose of 12.5mg EQDM/kg body
weight/day (Ørnsrud et al., 2011). However, in the present study,
elevated protein levels of CYP3A5, CYP2B6 and CYP2C8, all direct
targets of PXR, were observed at doses above 99mg EQDM/kg body
weight/day (Supplementary ﬁle A, Table S17). Thus, our data suggest
that, in addition to activation of NRF2, EQDM potentially acts through
induction of PXR/CAR-mediated pathways, including the PXR/CAR-
induced inhibition of β-oxidation through suppression of PPAR-α ex-
pression and may ultimately cause steatohepatitis, if the exposure is
continued.
4.1. Derivation of a health-based guidance value
Although an increase in relative spleen weights was noted, the most
signiﬁcant eﬀect of dietary EQDM exposure appeared to be liver toxi-
city with a dose-dependent change in relative liver weight, which was
associated with the development of microvesicular steatosis and ne-
crosis. The hepatosomatic index had the lowest BMD and the most
narrow 90% conﬁdence interval (BMDL05 of 4.4 mg EQDM/kg body
weight/day), and was thus regarded the most reliable estimation.
However, although the BMDs for histopathological ﬁndings were esti-
mated with wider conﬁcence intervals, as manifestations of treatment-
related physiological changes, these endpoints were considered more
critical in terms of biological relevance. In order to leave the largest
possible margin of safety, the reference point was based on the lowest
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BMDL for the most critical endpoint. Thus, occurrence of micro-
vesicular steatosis with a BMDL10 of 1.1 mg EQDM/kg body weight/day
is proposed as a Reference Point for risk assessment.
The Reference Point from the toxicity study can be used to establish
a health-based guidance value at which no adverse health eﬀects are
expected. Uncertainty factors are applied taking into account un-
certainty and variability such as inter- and intraspecies diﬀerences, and
commonly a default value of 200 is proposed for subchronic studies in
rodents (EFSA, 2012). With the BMDL10 of 1.1 mg EQDM/kg body
weight/day as a reference point, and taking into account an uncertainty
factor of 200, an ADI of 0.006mg EQDM/kg body weight can be de-
rived.
The proposed ADI of 0.006mg EQDM/kg body weight, corresponds
to an acceptable daily exposure of 0.36mg EQDM/day for a 60 kg adult.
For a person weighing 60 kg, eating one portion (300 g) of meat or ﬁsh,
these food items may not contain more than 1.2 mg EQDM/kg (as the
sole dietary source of EQDM). In the European Union, there are cur-
rently no Maximum Residue Limits (MRLs) established for EQ or its
metabolites in food products of animal origin. Limited data is available
on the occurrence of EQ and EQDM in various foods. Levels found in
farmed Atlantic salmon ﬁllet range between 0.33 and 1.45mg EQDM/
kg (Mean: 0.73 ± 0.29mg/kg) (Lundebye et al., 2010; He and
Ackman, 2000).
Of note, the measurement of EQ and EQDM in the feed used in the
present study revealed presence of ca. 3% EQ of the sum of EQ and
EQDM present in EQDM spiked feed. Although not optimal in terms of
experimental design, the presence of minor concentrations of EQ may
be considered relevant for human exposure, since EQ typically accounts
for a minor part of the sum EQ and EQDM found in farmed Atlantic
salmon ﬁllets exposed to EQ through their diet and reared according to
commercial farming practice (Bohne et al., 2008; Lundebye et al.,
2010).
Based on the mean EQDM levels reported, consumption of 300 g
farmed Atlantic salmon ﬁllet would contribute approximately 61% to
the proposed ADI. Thus, no exceedence of the ADI is expected from
consumption of one portion of farmed Atlantic salmon ﬁllet daily with
regards to EQDM exposure. Nevertheless, with approximately 61%
contribution to the ADI, farmed Atlantic salmon represents a major
source of dietary EQDM exposure. Since EQ may also be present in feed
for terrestrial farmed animals, the contribution of EQ and EQDM from
all relevant food sources warrants further investigation.
5. Conclusions
Taken together, the results obtained in the present study indicate
that subchronic dietary exposure to EQDM at levels above 10mg/kg
body weight/day disrupts hepatic lipid metabolism through impair-
ment of fatty acid β-oxidation, leading to increased lipid deposition and
steatosis in male BALB/c mice. Moreover, upstream analysis of hepatic
proteome proﬁles revealed that EQDM-induced hepatotoxicity is likely
mediated through activation of the orphan nuclear receptors PXR and/
or CAR as well as induction of a NRF2-mediated oxidative stress re-
sponse.
An ADI of 0.006mg EQDM/kg body weight was derived from the
benchmarch dose modelling of data obtained in the present study.
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